Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2 3Phase 1/2 3Phase 1 1

Status

Terminated 4Completed 3Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Breast 1

Conditions

Prostatic Neoplasms 2Triple Negative Breast Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 739Cisplatin 687Gemcitabine 641Bevacizumab 615Carboplatin 604Paclitaxel 600Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 360Capecitabine 342Filgrastim 333Etoposide 328Dexamethasone 312Irinotecan 309pembrolizumab 279Leucovorin 274Cetuximab 267Cytarabine 242Erlotinib Hydrochloride 231Prednisone 227Nivolumab 227Trastuzumab 225Bortezomib 221Vincristine 220Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Completed × orteronel × Clear all
NCT01990209 2022-06-30

Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)

SCRI Development Innovations, LLC

Phase 2 Completed
71 enrolled 23 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01549951 2016-06-01

Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer

Millennium Pharmaceuticals, Inc.

Phase 2 Completed
50 enrolled 22 charts
Genitourinary

Prostatic Neoplasms

NCT01046916 2016-04-04

Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen

Millennium Pharmaceuticals, Inc.

Phase 2 Completed
38 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡